NR0B2 and neoplasm: Given that activation of T cells within the tumor microenvironment and, as a consequence their ability to mediate tumor rejection, is a balance between the collective activity of ITAMs and ITIM/ITSMs within these cells, development of approaches which can block pinch-points in signaling pathways such as SHP1 and SHP2 may result in more effective immunotherapies.